Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$38.45 USD
-0.19 (-0.49%)
Updated Apr 22, 2024 11:56 AM ET
After-Market: $38.70 +0.25 (0.65%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
HALO 38.45 -0.19(-0.49%)
Will HALO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HALO
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Other News for HALO
Laughing Water Capital Q1 2024 Letter
Buy Rating Affirmed for Halozyme on OCREVUS SC Prospects and Enhanze Technology Potential
9 Analysts Have This To Say About Halozyme Therapeutics
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
Notable Two Hundred Day Moving Average Cross - HALO